Frauenfeld, 22 October 2025

Press release
Ad hoc announcement pursuant to Art. 53 LR

DocMorris successfully completes the placement of CHF 49.6 million Convertible Bonds due 2028

DocMorris Finance B.V. (the “Issuer”), a directly wholly-owned subsidiary of DocMorris AG (the “Company” or “DocMorris”), successfully completed the offering (the “New Bond Offering” or the “Offering”) of CHF 49.6 million senior unsecured bonds due 2028, guaranteed by the Company and convertible into newly issued and/or existing registered shares of the Company (the “New Bonds”).

DocMorris continuously seeks to optimise its balance sheet and funding costs to support its strategy and deliver sustainable and profitable growth. The proceeds from the New Bond Offering, will be used to fund the early buyback of its outstanding CHF 87.6 million 2026 convertible bond (“Outstanding Convertible Bonds due 2026”) and for general corporate purposes outside of Switzerland

On the back of successful pricing and provisional allocation of the New Bonds today, DocMorris invites all eligible holders of its Outstanding Convertible Bonds due 2026 to tender their bonds for cash during the tender offer period (the “Tender Offer”).

The Tender Offer purchase price is expected to be CHF 1,035 per bond corresponding to 103.5% of the par value, plus accrued and unpaid interest.

The cooling-off period under the Tender Offer is expected to start on 23 October 2025 and to end on 5 November 2025 and the Tender Offer period is expected to commence on 6 November 2025 and expire on 12 November 2025 at 4:00pm CET.

This press release is not an offer for the repurchase of the 2026 Bonds but only discloses the most important terms of the planned Tender Offer. The Tender Offer is solely made based on the publication of the Tender Offer notice today, 22 October 2025. The Tender Offer is executed independently and unconditionally from the New Bond Offering.

Offering of the New Bonds
The New Bonds will have a denomination of CHF 200,000 each and will be issued at par. Unless previously converted, redeemed or repurchased and cancelled, the New Bonds will be redeemed at par on the stated maturity date, which is expected to be on 24 August 2028.

The New Bonds will carry a coupon of 3.00% per annum, payable semi-annually in arrear, and have an initial conversion price of CHF 6.54 set at a premium of 20% over the reference share price of CHF 5.45, being the placement price per DocMorris share in the Concurrent Delta Placement (as defined below).

The New Bonds have been provisionally allocated to investors participating in the New Bond Offering. Such allocation of the New Bonds will be subject to a pro-rata reduction of the issue size relative to the aggregate principal amount of Bonds tendered under the Tender Offer (“Clawback”). Definitive allocations are expected to be announced after the end of the tender offer period.

The Issuer and the Company agreed to a lock-up period starting from the pricing date and ending 90 days following the settlement date, subject to customary exceptions.

The New Bond Offering is being conducted solely on a private placement basis to professional clients in Switzerland and private offering outside of Switzerland pursuant to RegS (Category 1), no Rule 144A.

Concurrent Delta Placement
The Joint Bookrunners have organized concurrently with the placement of the New Bonds due 2026, a simultaneous placement of existing shares of the Company (the “Concurrent Delta Placement”) on behalf of buyers of the New Bonds who wished to sell such shares in short sales to hedge the market risk of an investment in the New Bonds at a placement price that was determined by way of an accelerated bookbuilding process. The Company will not receive any proceeds from the Concurrent Delta Placement.

Indicative timeline of the transaction

Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, telemedicine and marketplace with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands. TeleClinic is Germany’s largest telemedicine platform, connecting patients with more than 5,000 physicians. DocMorris operates leading marketplaces for health and personal care products in Southern Europe. With its broad range of products and services, DocMorris is pursuing its vision of becoming the leading digital health companion for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,085 million serving more than10 million active customers in 2024. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

Disclaimer

THE CONTENTS OF THIS ANNOUNCEMENT HAVE BEEN PREPARED BY AND ARE THE SOLE RESPONSIBILITY OF DOCMORRIS AG (THE “COMPANY”) AND DOCMORRIS FINANCE B.V. (THE “ISSUER”). THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS FOR BACKGROUND PURPOSES ONLY AND DOES NOT PURPORT TO BE FULL OR COMPLETE. NO RELIANCE MAY BE PLACED BY ANY PERSON FOR ANY PURPOSE ON THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT OR ITS ACCURACY, FAIRNESS OR COMPLETENESS.

THIS INFORMATION DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES TO ANY PERSON IN THE UNITED STATES, AUSTRALIA, CANADA, ITALY, JAPAN, SOUTH AFRICA OR IN ANY JURISDICTION TO WHOM OR IN WHICH SUCH OFFER OR SOLICITATION IS UNLAWFUL. IT IS NOT BEING ISSUED IN COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED OR PROHIBITED BY LAW.

THIS INFORMATION IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THE DISTRIBUTION OF THIS ANNOUNCEMENT MAY BE RESTRICTED BY LAW IN CERTAIN JURISDICTIONS AND PERSONS INTO WHOSE POSSESSION ANY DOCUMENT OR OTHER INFORMATION REFERRED TO HEREIN COMES SHOULD INFORM THEMSELVES ABOUT AND OBSERVE SUCH RESTRICTION. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF ANY SUCH JURISDICTION. SECURITIES OF THE COMPANY OR THE ISSUER ARE NOT BEING PUBLICLY OFFERED OUTSIDE OF SWITZERLAND. IN PARTICULAR, THE SECURITIES OF THE COMPANY AND THE ISSUER REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES UNLESS REGISTERED UNDER THE US SECURITIES ACT OF 1933 (THE “SECURITIES ACT”) OR OFFERED IN A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OR UNDER THE APPLICABLE SECURITIES LAWS OF AUSTRALIA, CANADA OR JAPAN. SUBJECT TO CERTAIN EXCEPTIONS, THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO OR FOR THE ACCOUNT OF U.S. PERSONS EXCEPT IN AN “OFFSHORE TRANSACTION” IN ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT OR FOR THE ACCOUNT OR BENEFIT OF ANY NATIONAL, RESIDENT OR CITIZEN OF AUSTRALIA, CANADA OR JAPAN. THIS DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS ACCORDING TO THE SWISS FEDERAL ACT ON FINANCIAL SERVICES.

IN EACH MEMBER STATE OF THE EUROPEAN ECONOMIC AREA AND THE UNITED KINGDOM (EACH, A “RELEVANT STATE”), THIS ANNOUNCEMENT AND ANY OFFER IF MADE SUBSEQUENTLY IS DIRECTED ONLY AT PERSONS WHO ARE “QUALIFIED INVESTORS” WITHIN THE MEANING OF THE PROSPECTUS REGULATION (REGULATION (EU) 2017/1129) (“QUALIFIED INVESTORS”). IN THE UNITED KINGDOM THIS ANNOUNCEMENT IS DIRECTED EXCLUSIVELY AT QUALIFIED INVESTORS (I) WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE “ORDER”) OR (II) WHO FALL WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, AND (III) TO WHOM IT MAY OTHERWISE LAWFULLY BE COMMUNICATED, AND ANY INVESTMENT ACTIVITY TO WHICH IT RELATES WILL ONLY BE ENGAGED IN WITH SUCH PERSONS AND IT SHOULD NOT BE RELIED ON BY ANYONE OTHER THAN SUCH PERSONS.

THIS ANNOUNCEMENT MAY INCLUDE STATEMENTS THAT ARE, OR MAY BE DEEMED TO BE, “FORWARD-LOOKING STATEMENTS”. THESE FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY THE USE OF FORWARD-LOOKING TERMINOLOGY, INCLUDING THE TERMS “BELIEVES”, “ESTIMATES”, “PLANS”, “PROJECTS”, “ANTICIPATES”, “EXPECTS”, “INTENDS”, “MAY”, “WILL” OR “SHOULD” OR, IN EACH CASE, THEIR NEGATIVE OR OTHER VARIATIONS OR COMPARABLE TERMINOLOGY, OR BY DISCUSSIONS OF STRATEGY, PLANS, OBJECTIVES, GOALS, FUTURE EVENTS OR INTENTIONS. FORWARD-LOOKING STATEMENTS MAY AND OFTEN DO DIFFER MATERIALLY FROM ACTUAL RESULTS. ANY FORWARD-LOOKING STATEMENTS REFLECT THE ISSUER’S OR THE COMPANY’S CURRENT VIEW WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS RELATING TO FUTURE EVENTS AND OTHER RISKS, UNCERTAINTIES AND ASSUMPTIONS RELATING TO THE GROUP’S BUSINESS, RESULTS OF OPERATIONS, FINANCIAL POSITION, LIQUIDITY, PROSPECTS, GROWTH OR STRATEGIES. FORWARD-LOOKING STATEMENTS SPEAK ONLY AS OF THE DATE THEY ARE MADE. EACH OF THE ISSUER, THE COMPANY, THE JOINT BOOKRUNNERS AND THEIR RESPECTIVE AFFILIATES EXPRESSLY DISCLAIMS ANY OBLIGATION OR UNDERTAKING TO UPDATE, REVIEW OR REVISE ANY FORWARD LOOKING STATEMENT CONTAINED IN THIS ANNOUNCEMENT WHETHER AS A RESULT OF NEW INFORMATION, FUTURE DEVELOPMENTS OR OTHERWISE.

THIS PUBLICATION CONSTITUTES NEITHER A PROSPECTUS OR A SIMILAR COMMUNICATION WITHIN THE MEANING OF THE ARTICLES 35 ET SEQQ. AND 69 OF THE SWISS FINANCIAL SERVICES ACT OR UNDER ANY OTHER LAW OR A LISTING PROSPECTUS WITHIN THE MEANING OF THE APPLICABLE LISTING RULES OF ANY STOCK EXCHANGE. ANY PURCHASE OF SHARES OF THE COMPANY IN THE PROPOSED OFFERING SHOULD BE MADE SOLELY ON THE BASIS OF PUBLICLY AVAILABLE INFORMATION. THE INFORMATION IN THIS ANNOUNCEMENT IS SUBJECT TO CHANGE. THE JOINT BOOKRUNNERS ARE ACTING EXCLUSIVELY FOR ISSUER AND THE COMPANY AND NO-ONE ELSE IN CONNECTION WITH THE OFFERING. THEY WILL NOT REGARD ANY OTHER PERSON AS THEIR RESPECTIVE CLIENTS IN RELATION TO THE OFFERING AND WILL NOT BE RESPONSIBLE TO ANYONE OTHER THAN ISSUER AND THE COMPANY FOR PROVIDING THE PROTECTIONS AFFORDED TO THEIR RESPECTIVE CLIENTS, NOR FOR PROVIDING ADVICE IN RELATION TO THE OFFERING, THE CONTENTS OF THIS ANNOUNCEMENT OR ANY TRANSACTION, ARRANGEMENT OR OTHER MATTER REFERRED TO HEREIN.

IN CONNECTION WITH THE OFFERING OF THE NEW BONDS AND THE SHARES, THE JOINT BOOKRUNNERS AND ANY OF THEIR AFFILIATES MAY TAKE UP A PORTION OF THE SECURITIES IN THE OFFERINGS AS A PRINCIPAL POSITION AND IN THAT CAPACITY, MAY RETAIN, PURCHASE, SELL, OFFER TO SELL FOR THEIR OWN ACCOUNTS SUCH SECURITIES AND OTHER SECURITIES OF THE ISSUER OR THE COMPANY OR RELATED INVESTMENTS IN CONNECTION WITH THE OFFERINGS OR OTHERWISE. ACCORDINGLY, REFERENCES RELATED TO THE NEW BONDS,  BEING ISSUED, OFFERED, SUBSCRIBED, ACQUIRED, PLACED OR OTHERWISE DEALT IN SHOULD BE READ AS INCLUDING ANY ISSUE OR OFFER TO, OR SUBSCRIPTION, ACQUISITION, PLACING OR DEALING BY THE JOINT BOOKRUNNERS AND ANY OF THEIR AFFILIATES ACTING IN SUCH CAPACITY. IN ADDITION, THE JOINT BOOKRUNNERS, AND ANY OF THEIR AFFILIATES MAY ENTER INTO FINANCING ARRANGEMENTS (INCLUDING SWAPS, WARRANTS OR CONTRACTS FOR DIFFERENCES) WITH INVESTORS IN CONNECTION WITH WHICH THE JOINT BOOKRUNNERS AND ANY OF THEIR AFFILIATES MAY FROM TIME TO TIME ACQUIRE, HOLD OR DISPOSE OF SECURITIES OF THE ISSUER OR THE COMPANY. THE JOINT BOOKRUNNERS DO NOT INTEND TO DISCLOSE THE EXTENT OF ANY SUCH INVESTMENT OR TRANSACTIONS OTHERWISE THAN IN ACCORDANCE WITH ANY LEGAL OR REGULATORY OBLIGATIONS TO DO SO.

NONE OF THE JOINT BOOKRUNNERS OR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES, ADVISERS OR AGENTS ACCEPTS ANY RESPONSIBILITY OR LIABILITY WHATSOEVER FOR OR MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, AS TO THE TRUTH, ACCURACY OR COMPLETENESS OF THE INFORMATION IN THIS ANNOUNCEMENT (OR WHETHER ANY INFORMATION HAS BEEN OMITTED FROM THE ANNOUNCEMENT) OR ANY OTHER INFORMATION RELATING TO THE ISSUER OR THE COMPANY, THEIR SUBSIDIARIES OR ASSOCIATED COMPANIES, WHETHER WRITTEN, ORAL OR IN A VISUAL OR ELECTRONIC FORM, AND HOWSOEVER TRANSMITTED OR MADE AVAILABLE OR FOR ANY LOSS HOWSOEVER ARISING FROM ANY USE OF THIS ANNOUNCEMENT OR ITS CONTENTS OR OTHERWISE ARISING IN CONNECTION THEREWITH.

NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER TO ACQUIRE SECURITIES IN ANY JURISDICTION. ANY INVESTOR SHOULD MAKE HIS INVESTMENT DECISION FOR THE PURCHASE OF THE SHARES ON PUBLICLY AVAILABLE INFORMATION.

Viromed Medical AG: Reallocation of Viromed shares broadens investor base

Rellingen, October 21, 2025 – Viromed Medical AG (“Viromed”; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, Viromed is expanding its shareholder base by initiating the reallocation of Viromed shares held by the CEO and founder Uwe Perbandt. The company is thus setting the course for the strategic development of its shareholder structure and the transition to the next phase of growth.

Uwe Perbandt has financed the company primarily from his own resources since its founding in 2020, enabling the complete development of the product pipeline up to the upcoming market launch of the ViroCAP® systems. This consistent self-financing meant that a capital increase and thus a dilution of existing shareholders could be avoided.

The proceeds from the sale of shares by Mr. Perbandt in the past – both on the stock exchange and through private placements – were used entirely to refinance Viromed Medical AG through shareholder loans from the Management Board member and majority shareholder. The most recent sales in the past few weeks were also used exclusively to further finance the company.

Uwe Perbandt, CEO of Viromed Medical AG, explains: “I have built up and financed Viromed over many years on my own initiative in order to enable the development of our cold plasma technology and market entry without dilution for shareholders. With the planned further reallocation of Viromed shares from my portfolio I would like to give other shareholders the opportunity to accompany us on our upcoming growth course. My personal commitment and my strategic responsibility and assessment of Viromed’s prospects for success remain unaffected by this.“

With regard to these further placements, Mr. Perbandt plans to have them carried out by a specialized broker in order to execute the planned transactions on the market in a way that minimizes the impact on the share price. Placements of up to 500,000 shares are planned in this manner over the next six months. ICF BANK AG Wertpapierhandelsbank is to be commissioned to carry out the measure.

About Viromed Medical AG

Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential.

www.viromed-medical-ag.de

Contact Viromed

E-Mail: kontakt@viromed-medical.de
 

Press contact

E-mail: viromed@kirchhoff.de

Frauenfeld, 21 October 2025

Press release

Ad hoc announcement pursuant to Art. 53 LR

DocMorris launches approx. CHF 45 million Convertible Bonds due 2028 to fund early buyback of Convertible Bonds 2026

DocMorris Finance B.V. (the “Issuer”), a directly wholly-owned subsidiary of DocMorris AG (the “Company” or “DocMorris”), is launching an offering (the “New Bond Offering” or the “Offering”) of approximately CHF 45 million senior unsecured bonds due 2028, guaranteed by the Company and convertible into newly issued and/or existing registered shares of the Company (the “New Bonds”).

DocMorris continuously seeks to optimise its balance sheet and funding costs to support its strategy and deliver sustainable and profitable growth. With today’s transaction, the Company intends to fund the envisaged early buyback of the CHF 95.0 million Convertible Bond due in September 2026 of which CHF 87.6 million is outstanding (the “2026 Bonds”).

Subject to successful pricing and provisional allocation of the New Bonds today, DocMorris plans to invite all eligible holders of its 2026 Bonds to tender their bonds for cash during the tender offer period (the “Tender Offer”).

The Tender Offer purchase price is expected to be CHF 1,035 per bond corresponding to 103.5% of the par value, plus accrued and unpaid interest.

The cooling-off period under the Tender Offer is expected to start on 23 October 2025 and to end on 4 November 2025 and the Tender Offer period is expected to commence on 6 November 2025 and expire on 12 November 2025 at 4:00pm CET.

This press release is not an offer for the repurchase of the 2026 Bonds but only discloses the most important terms of the planned Tender Offer. The Tender Offer is solely made based on the planned publication of the Tender Offer notice tomorrow, 22 October 2025. The Tender Offer is executed independently and unconditionally from the New Bond Offering.

Offering of the New Bonds
The New Bonds will have a denomination of CHF 200,000 each and will be issued at par. Unless previously converted, redeemed or repurchased and cancelled, the New Bonds will be redeemed at par on the stated maturity date, which is expected to be on 24 August 2028.

The New Bonds are expected to carry a coupon of between 2.50% and 3.00% per annum, payable semi-annually in arrear, and have an initial conversion price set at an expected premium of between 20% and 25% over the reference share price, being the placement price per DocMorris share in the Concurrent Delta Placement (as defined below).

The Company’s existing stock lending agreement will be amended, to enable its drawdown also in relation to the New Bonds for the duration of the New Bonds (unless bought back, redeemed or converted and then it will be reduced on a pro rata basis) for the purpose of facilitating investors’ hedging activities and will amount to up to 5.0 million existing and new shares of the Company, representing up to 9.8% of the Company’s issued share capital, as long as the New Bonds and the outstanding CHF 200 million Convertible Bond due in May 2029 (the “2029 Bonds”) are outstanding. Such number of total shares of the Guarantor can be further increased at later stage to cover the combined parity of any outstanding amount of the 2026 Bonds, the 2029 Bonds and the New Bonds (unless bought back, redeemed or converted, and then it will be reduced on a pro rata basis).

Allocations are provisional and at the Issuer’s full discretion, subject to a reduction of the issue size relative to the aggregate principal amount of Bonds tendered under the Tender Offer (the “Clawback”). Definitive allocations are expected to be announced after the end of the tender offer period.

The Issuer and the Company agreed to a lock-up period starting from the pricing date and ending 90 days following the settlement date, subject to customary exceptions.

The New Bond Offering is being conducted solely on a private placement basis to professional clients in Switzerland and private offering outside of Switzerland pursuant to RegS (Category 1), no Rule 144A.

Concurrent Delta Placement
The Joint Bookrunners have agreed with the Company that concurrently with the placement of the Convertible Bonds, they intend to conduct a simultaneous placement of existing shares of the Company (the “Concurrent Delta Placement”) on behalf of buyers of the Convertible Bonds who wish to sell such shares in short sales to hedge the market risk of an investment in the Convertible Bonds at a placement price to be determined by way of an accelerated bookbuilding process. The Company will not receive any proceeds from the Concurrent Delta Placement.

Indicative timeline of the transaction

Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, telemedicine and marketplace with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands. TeleClinic is Germany’s largest telemedicine platform, connecting patients with more than 5,000 physicians. DocMorris operates leading marketplaces for health and personal care products in Southern Europe. With its broad range of products and services, DocMorris is pursuing its vision of becoming the leading digital health companion for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,085 million serving more than10 million active customers in 2024. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

Disclaimer

THE CONTENTS OF THIS ANNOUNCEMENT HAVE BEEN PREPARED BY AND ARE THE SOLE RESPONSIBILITY OF DOCMORRIS AG (THE “COMPANY”) AND DOCMORRIS FINANCE B.V. (THE “ISSUER”). THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS FOR BACKGROUND PURPOSES ONLY AND DOES NOT PURPORT TO BE FULL OR COMPLETE. NO RELIANCE MAY BE PLACED BY ANY PERSON FOR ANY PURPOSE ON THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT OR ITS ACCURACY, FAIRNESS OR COMPLETENESS.

THIS INFORMATION DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES TO ANY PERSON IN THE UNITED STATES, AUSTRALIA, CANADA, ITALY, JAPAN, SOUTH AFRICA OR IN ANY JURISDICTION TO WHOM OR IN WHICH SUCH OFFER OR SOLICITATION IS UNLAWFUL. IT IS NOT BEING ISSUED IN COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED OR PROHIBITED BY LAW,

THIS INFORMATION IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THE DISTRIBUTION OF THIS ANNOUNCEMENT MAY BE RESTRICTED BY LAW IN CERTAIN JURISDICTIONS AND PERSONS INTO WHOSE POSSESSION ANY DOCUMENT OR OTHER INFORMATION REFERRED TO HEREIN COMES SHOULD INFORM THEMSELVES ABOUT AND OBSERVE SUCH RESTRICTION. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF ANY SUCH JURISDICTION. SECURITIES OF THE COMPANY OR THE ISSUER ARE NOT BEING PUBLICLY OFFERED OUTSIDE OF SWITZERLAND. IN PARTICULAR, THE SECURITIES OF THE COMPANY AND THE ISSUER REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES UNLESS REGISTERED UNDER THE US SECURITIES ACT OF 1933 (THE “SECURITIES ACT”) OR OFFERED IN A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OR UNDER THE APPLICABLE SECURITIES LAWS OF AUSTRALIA, CANADA OR JAPAN. SUBJECT TO CERTAIN EXCEPTIONS, THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO OR FOR THE ACCOUNT OF U.S. PERSONS EXCEPT IN AN “OFFSHORE TRANSACTION” IN ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT OR FOR THE ACCOUNT OR BENEFIT OF ANY NATIONAL, RESIDENT OR CITIZEN OF AUSTRALIA, CANADA OR JAPAN. THIS DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS ACCORDING TO THE SWISS FEDERAL ACT ON FINANCIAL SERVICES.

IN EACH MEMBER STATE OF THE EUROPEAN ECONOMIC AREA AND THE UNITED KINGDOM (EACH, A “RELEVANT STATE”), THIS ANNOUNCEMENT AND ANY OFFER IF MADE SUBSEQUENTLY IS DIRECTED ONLY AT PERSONS WHO ARE “QUALIFIED INVESTORS” WITHIN THE MEANING OF THE PROSPECTUS REGULATION (REGULATION (EU) 2017/1129) (“QUALIFIED INVESTORS”). IN THE UNITED KINGDOM THIS ANNOUNCEMENT IS DIRECTED EXCLUSIVELY AT QUALIFIED INVESTORS (I) WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE “ORDER”) OR (II) WHO FALL WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, AND (III) TO WHOM IT MAY OTHERWISE LAWFULLY BE COMMUNICATED, AND ANY INVESTMENT ACTIVITY TO WHICH IT RELATES WILL ONLY BE ENGAGED IN WITH SUCH PERSONS AND IT SHOULD NOT BE RELIED ON BY ANYONE OTHER THAN SUCH PERSONS.

THIS ANNOUNCEMENT MAY INCLUDE STATEMENTS THAT ARE, OR MAY BE DEEMED TO BE, “FORWARD-LOOKING STATEMENTS”. THESE FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY THE USE OF FORWARD-LOOKING TERMINOLOGY, INCLUDING THE TERMS “BELIEVES”, “ESTIMATES”, “PLANS”, “PROJECTS”, “ANTICIPATES”, “EXPECTS”, “INTENDS”, “MAY”, “WILL” OR “SHOULD” OR, IN EACH CASE, THEIR NEGATIVE OR OTHER VARIATIONS OR COMPARABLE TERMINOLOGY, OR BY DISCUSSIONS OF STRATEGY, PLANS, OBJECTIVES, GOALS, FUTURE EVENTS OR INTENTIONS. FORWARD-LOOKING STATEMENTS MAY AND OFTEN DO DIFFER MATERIALLY FROM ACTUAL RESULTS. ANY FORWARD-LOOKING STATEMENTS REFLECT THE ISSUER’S OR THE COMPANY’S CURRENT VIEW WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS RELATING TO FUTURE EVENTS AND OTHER RISKS, UNCERTAINTIES AND ASSUMPTIONS RELATING TO THE GROUP’S BUSINESS, RESULTS OF OPERATIONS, FINANCIAL POSITION, LIQUIDITY, PROSPECTS, GROWTH OR STRATEGIES. FORWARD-LOOKING STATEMENTS SPEAK ONLY AS OF THE DATE THEY ARE MADE. EACH OF THE ISSUER, THE COMPANY, THE JOINT BOOKRUNNERS AND THEIR RESPECTIVE AFFILIATES EXPRESSLY DISCLAIMS ANY OBLIGATION OR UNDERTAKING TO UPDATE, REVIEW OR REVISE ANY FORWARD LOOKING STATEMENT CONTAINED IN THIS ANNOUNCEMENT WHETHER AS A RESULT OF NEW INFORMATION, FUTURE DEVELOPMENTS OR OTHERWISE.

THIS PUBLICATION CONSTITUTES NEITHER A PROSPECTUS OR A SIMILAR COMMUNICATION WITHIN THE MEANING OF THE ARTICLES 35 ET SEQQ. AND 69 OF THE SWISS FINANCIAL SERVICES ACT OR UNDER ANY OTHER LAW OR A LISTING PROSPECTUS WITHIN THE MEANING OF THE APPLICABLE LISTING RULES OF ANY STOCK EXCHANGE. ANY PURCHASE OF SHARES OF THE COMPANY IN THE PROPOSED OFFERING SHOULD BE MADE SOLELY ON THE BASIS OF PUBLICLY AVAILABLE INFORMATION. THE INFORMATION IN THIS ANNOUNCEMENT IS SUBJECT TO CHANGE THE JOINT BOOKRUNNERS ARE ACTING EXCLUSIVELY FOR ISSUER AND THE COMPANY AND NO-ONE ELSE IN CONNECTION WITH THE OFFERING. THEY WILL NOT REGARD ANY OTHER PERSON AS THEIR RESPECTIVE CLIENTS IN RELATION TO THE OFFERING AND WILL NOT BE RESPONSIBLE TO ANYONE OTHER THAN ISSUER AND THE COMPANY FOR PROVIDING THE PROTECTIONS AFFORDED TO THEIR RESPECTIVE CLIENTS, NOR FOR PROVIDING ADVICE IN RELATION TO THE OFFERING, THE CONTENTS OF THIS ANNOUNCEMENT OR ANY TRANSACTION, ARRANGEMENT OR OTHER MATTER REFERRED TO HEREIN.

IN CONNECTION WITH THE OFFERING OF THE NEW BONDS AND THE SHARES, THE JOINT BOOKRUNNERS AND ANY OF THEIR AFFILIATES MAY TAKE UP A PORTION OF THE SECURITIES IN THE OFFERINGS AS A PRINCIPAL POSITION AND IN THAT CAPACITY, MAY RETAIN, PURCHASE, SELL, OFFER TO SELL FOR THEIR OWN ACCOUNTS SUCH SECURITIES AND OTHER SECURITIES OF THE ISSUER OR THE COMPANY OR RELATED INVESTMENTS IN CONNECTION WITH THE OFFERINGS OR OTHERWISE. ACCORDINGLY, REFERENCES RELATED TO THE NEW BONDS, BEING ISSUED, OFFERED, SUBSCRIBED, ACQUIRED, PLACED OR OTHERWISE DEALT IN SHOULD BE READ AS INCLUDING ANY ISSUE OR OFFER TO, OR SUBSCRIPTION, ACQUISITION, PLACING OR DEALING BY THE JOINT BOOKRUNNERS AND ANY OF THEIR AFFILIATES ACTING IN SUCH CAPACITY. IN ADDITION, THE JOINT BOOKRUNNERS, AND ANY OF THEIR AFFILIATES MAY ENTER INTO FINANCING ARRANGEMENTS (INCLUDING SWAPS, WARRANTS OR CONTRACTS FOR DIFFERENCES) WITH INVESTORS IN CONNECTION WITH WHICH THE JOINT BOOKRUNNERS AND ANY OF THEIR AFFILIATES MAY FROM TIME TO TIME ACQUIRE, HOLD OR DISPOSE OF SECURITIES OF THE ISSUER OR THE COMPANY. THE JOINT BOOKRUNNERS DO NOT INTEND TO DISCLOSE THE EXTENT OF ANY SUCH INVESTMENT OR TRANSACTIONS OTHERWISE THAN IN ACCORDANCE WITH ANY LEGAL OR REGULATORY OBLIGATIONS TO DO SO.

NONE OF THE JOINT BOOKRUNNERS OR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES, ADVISERS OR AGENTS ACCEPTS ANY RESPONSIBILITY OR LIABILITY WHATSOEVER FOR OR MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, AS TO THE TRUTH, ACCURACY OR COMPLETENESS OF THE INFORMATION IN THIS ANNOUNCEMENT (OR WHETHER ANY INFORMATION HAS BEEN OMITTED FROM THE ANNOUNCEMENT) OR ANY OTHER INFORMATION RELATING TO THE ISSUER OR THE COMPANY, THEIR SUBSIDIARIES OR ASSOCIATED COMPANIES, WHETHER WRITTEN, ORAL OR IN A VISUAL OR ELECTRONIC FORM, AND HOWSOEVER TRANSMITTED OR MADE AVAILABLE OR FOR ANY LOSS HOWSOEVER ARISING FROM ANY USE OF THIS ANNOUNCEMENT OR ITS CONTENTS OR OTHERWISE ARISING IN CONNECTION THEREWITH.

NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER TO ACQUIRE SECURITIES IN ANY JURISDICTION. ANY INVESTOR SHOULD MAKE HIS INVESTMENT DECISION FOR THE PURCHASE OF THE SHARES ON PUBLICLY AVAILABLE INFORMATION.

The European medical cannabis and industrial hemp group SYNBIOTIC SE (ISIN DE000A3E5A59 | WKN A3E5A5) considers the bill introduced by Bündnis 90/Die Grünen on 7 October 2025 to amend the Consumer Cannabis Act (KCanG) an important step towards greater legal certainty, innovation, and competitiveness for the German hemp industry. At the same time, the company is closely monitoring the planned tightening of the Medical Cannabis Act (MedCanG).

Momentum for the hemp industry: liberalization of industrial hemp opens new perspectives

The Greens’ proposal aims to remove the so-called “intoxication clause”, raise the THC limit for industrial hemp from 0.3% to 1%, and permit indoor cultivation. This would align Germany with practices already established in other EU countries such as the Czech Republic. The reform would significantly expand the economic scope for cultivation, processing, and product development within the industrial hemp sector.

According to SYNBIOTIC, the proposed liberalization would represent an important impulse for sustainable agriculture, innovation, and regional value creation. The Group is well integrated across Europe and strongly positioned in the industrial hemp market through subsidiaries such as Hempro International, Hemp Factory, and Ilesol, and therefore sees significant potential to further develop hemp as a sustainable raw material for future industries.

Daniel Kruse, CEO of SYNBIOTIC: “For decades, we have been advocating for evidence-based and innovation-driven hemp policies. The Greens’ initiative is a signal of progress and reinforces confidence in the future of industrial hemp. As President of the European Industrial Hemp Association (EIHA), entrepreneur of 30 years, and CEO of SYNBIOTIC, I hope that Federal Agriculture Minister Alois Rainer will recognize the enormous potential of this crop for agriculture, industry, and trade.”

Criticism of the MedCanG reform: patient care must not suffer

The draft bill presented by Federal Health Minister Nina Warken (CDU) to amend the Medical Cannabis Act has sparked broad criticism. It includes a ban on mail-order sales and stricter rules for online prescriptions. Industry associations, patient initiatives, and companies warn of significant risks.

• 86% of respondents in a recent survey expect the changes to worsen patient access and strengthen the black market.
• The SPD parliamentary group announced that it would not support the bill in its current form, calling it “overregulated” and “hostile to patients.”
• Industry leaders, including the CEOs of Bloomwell, Sanity Group, and Demecan, criticized the proposed ban on mail-order sales as a “setback for patient care and digitalization.”
• The Federal Association of German Mail-Order Pharmacies (BVDVA) rejected the plans as “not in the interest of patients,” describing them as “unjustified restrictions on reputable providers.”

SYNBIOTIC SE calls for objective and differentiated regulation. A functioning medical cannabis market requires reliability, quality standards, and digital healthcare solutions—not sweeping restrictions that stifle progress. At the same time, the company emphasizes that unregulated telemedicine platforms must not be allowed to create parallel systems outside of existing healthcare structures.

Daniel Kruse, CEO of SYNBIOTIC, adds: “Patient access, product safety, and medical quality must not be played off against each other. Modern healthcare requires trust in doctors and pharmacies—both in-person and online—alongside regulated suppliers and clear standards, but not blunt prohibitions.”

SYNBIOTIC: dual strategy combining innovation and responsibility

With its engagement in both medical cannabis and industrial hemp, SYNBIOTIC positions itself as an investment platform for two billion-euro markets that share similar needs and vast potential. Both sectors offer significant opportunities for sustainable value creation—provided that stable, modern, and science-based regulatory frameworks are established.

SYNBIOTIC will continue to actively participate in political and regulatory processes to promote practical and forward-looking solutions for patients, customers, farmers, industry, and investors alike.

Publisher
SYNBIOTIC SE
Daniel Kruse
CEO
Münsterstraße 336
40470 Düsseldorf
Germany
www.synbiotic.com

Media
Rüdiger Tillmann
SYNBIOTIC Public Relations Manager
Email ruediger.tillmann@synbiotic.com
Mobile +49 171 3677028
c/o JOLE.group

About SYNBIOTIC
SYNBIOTIC is a listed group of companies in the medical cannabis and industrial hemp sector with a buy-and-build investment strategy focussed on Europe. The Group covers the entire value chain from cultivation to production and retail – from the field to shelf. The subsidiaries’ core businesses are research and development, production and the commercialisation of medical cannabis, industrial hemp and CBD products.
SYNBIOTIC is pursuing a clear pan-European strategy of further expanding its business areas in order to cover the relevant growth markets while minimising risks and increasing opportunities for investors through diversification.

Press Release // October 21, 2025

Formycon’s FYB201/Ranivisio^® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe

• Innovative pre-filled syringe (PFS) with high standards for intravitreal injections¹ offers improved handling, high dosing accuracy and greater convenience for applicants
• Teva Pharmaceutical Industries Ltd. to commercialize FYB201/Ranivisio^®2 PFS across Europe
• Market launch of FYB201/Ranivisio^® PFS started in France in October 2025, with additional countries – including Germany – to follow in a staggered approach
• FYB201/Ranivisio^® PFS expands therapeutic options and maximizes the potential reach of the ranibizumab biosimilar FYB201 throughout Europe

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”), Bioeq AG (“Bioeq”) and Teva Pharmaceutical Industries Ltd. (NYSE/TASE: TEVA, “Teva”) jointly announce the European launch of FYB201/Ranivisio^® as the first Lucentis^®3 biosimilar available in an EMA-approved innovative pre-filled syringe (“PFS”) presentation. The launch started in France in October 2025, with additional countries – including Germany – to follow in a staggered approach.

FYB201/Ranivisio^® will be the first Lucentis^® biosimilar in Europe to be offered as a pre-filled syringe, providing patients and healthcare professionals with a convenient, and efficient treatment option. Teva, Bioeq’s established commercialization partner for the vial presentation since 2022, will now also market the PFS, significantly expanding market reach and therapeutic access. This collaboration combines Teva’s deep commercial experience in biosimilars and its extensive distribution network and broad sales and marketing reach across Europe, with Formycon’s capabilities in the development of biosimilar medicines for highly regulated countries.

The innovative PFS technology has been specifically designed for intravitreal injections and is characterized by high dosing accuracy, low injection pressure, and a minimized risk of application errors – key factors in ophthalmic care. The silicon-oil free syringe-device combined with a modern sterilization technology is setting high and innovative standards.

The ready-to-use syringe reduces preparation time and supports efficient administration for patients with neovascular (wet) age-related macular degeneration (nAMD) and other serious retinal diseases.

Dr. Stefan Glombitza, CEO of Formycon, comments: “The launch of our FYB201 pre-filled syringe is another testament to Formycon’s outstanding development expertise paired with innovation power. By introducing the first ranibizumab biosimilar in this modern pre-filled syringe presentation, we are setting new standards in convenience, safety and efficiency for ophthalmic treatments and are underlining our strong commitment to advancing ophthalmic care. The pre-filled syringe not only streamlines clinical workflows by reducing preparation time and minimizing the risk of application errors, it also offers high dosing accuracy and ease of use – features that are highly valued by ophthalmologists in daily practice.

We are confident that this new presentation will enable our commercial partner Teva to reach even more healthcare professionals and patients, and ultimately improve access to FYB201/Ranivisio^®”

Michał Nitka, Teva SVP Head Generics Europe & Global Head OTC, added: “We are pleased to offer healthcare professionals and patients a treatment solution, further expanding access to high-quality medicines. At Teva, we are committed to pushing boundaries to deliver the right medicines whenever they are needed. Through our partnership with Formycon, we are accelerating the availability of therapies and broadening Teva’s biosimilars portfolio, in line with our Pivot to Growth strategy, while leveraging our capabilities to serve patients with the treatments they need.”

FYB201/Ranivisio^® (ranibizumab) is used to treat severe visual impairments such as wet age-related macular degeneration (nAMD) and other retinopathies. FYB201 is owned by Bioeq AG, a joint venture between Formycon AG and Polpharma Biologics Group BV. The Biosimilar product is currently available in a total of 21 countries in Europe, North America and the MENA region.

——————–

¹⁾ An intravitreal injection refers to the injection of a medication into the vitreous body of the eye.
²⁾ Ranivisio^® is a registered trademark of Bioeq AG.
³⁾ Lucentis^® is a registered trademark of Genentech Inc.

About Formycon:
Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/ranibizumab and FYB202/ustekinumab, Formycon already has two biosimilars on the market. Another biosimilar, FYB203/aflibercept, has been approved by the FDA, EMA, and MHRA. Four pipeline candidates are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines.

Formycon AG is headquartered in Munich, listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY and is part of the SDAX selection index. Further information can be found at: https://www.formycon.com/

About Bioeq:
Bioeq is a Swiss biopharmaceutical joint venture between the Polpharma Biologics Group and Formycon AG. Bioeq develops, licenses and commercializes biosimilars. www.bioeq.ch

About Teva Pharmaceutical Industries Ltd.:
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

About Biosimilars:
Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare systems. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.

Contact:
Sabrina Müller,
Director Investor Relations & Corporate Communications,
Formycon AG
Fraunhoferstr. 15
82152 Planegg-Martinsried
Germany

Tel.: +49 (0) 89 – 86 46 67 149
Fax: + 49 (0) 89 – 86 46 67 110
Sabrina.Mueller@formycon.com 

Disclaimer:
This press release may contain forward-looking statements and information which are based on Formycon’s current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.

ActiTrexx completes treatment of last patient with novel regulatory T cell therapy against Graft-versus-Host Disease

• Phase Ib/II study with Actileucel, a novel cellular product based on activated regulatory T cells for prevention of Graft-versus-Host Disease (GvHD)
• Follow-up is ongoing to evaluate the safety of Actileucel treatment as well as frequency and severity of potential GvHD
• Actileucel is the first regulatory T cell therapy from an unmatched third-party donor

Mainz, Germany, 20 October 2025 – ActiTrexx GmbH, a clinical-stage company focusing on the activation of regulatory T cells, has completed the treatment of the final patient in its first-in-human study with Actileucel, its novel allogeneic cell therapy for the prevention and treatment of Graft-versus-Host Disease (GvHD).

Actileucel is generated by activating regulatory T cells (Tregs) isolated from an unmatched, third-party donor via a fast proprietary process with a vein-to-vein time of 24 hours.

Prof. Dr. Andrea Tüttenberg, CEO of ActiTrexx, said: “The completion of patient treatment in our Phase Ib/II study marks an important milestone for our Actileucel program. Our approach, which uses activated regulatory T cells from a 3^rd party donor who does not need to match the patient’s tissue markers, has the potential to control or prevent GvHD, a serious and often life-threatening complication following stem cell transplantation. Follow-up continues and once the full dataset is available, we plan on publishing the results in a peer-reviewed journal. The Nobel Prize in Medicine/Physiology awarded this year highlights the fundamental role of regulatory T cells in immune system control, which underlines the scientific rationale behind our approach.”

Prof. Dr. Martin Bornhäuser, Chief Physician and Director Department of Medicine I, University Hospital Carl Gustav Carus in Dresden, commented: “ActiTrexx’s proprietary method for activating and generating regulatory T cells is unique worldwide, highly innovative and represents a promising approach in the field of cell therapy. The use of regulatory T cells from a second donor to potentially control or prevent GvHD offers a novel strategy for a complication that affects half of all stem cell transplant recipients and has historically high mortality.”

The prospective open, single-arm non-randomized multicentric Phase Ib/II study included ten patients who had recently undergone an allogeneic haematopoietic stem cell transplantation as treatment for haematological malignancies such as acute leukemia.

Patients received a single treatment with Actileucel with a follow-up of six months, which is still ongoing for the last patients. Patients in the study were treated with increasing doses of activated regulatory T cells in three cohorts.

Primary endpoint of the study is the safety and tolerability of Actileucel treatment, while secondary endpoints include an assessment of the frequency and severity of GvHD in treated patients as well as of the feasibility of Actileucel manufacturing. The trial is being conducted at four sites in Germany, the III. Medical Clinic of the University Medical Center Mainz, the University Hospital Carl Gustav Carus in Dresden, the University Medical Centre of Münster, and the Internal Medicine II of the St. Johannes Hospital Dortmund.

“We are happy that the manufacturing process at ActiTrexx and the treatments at the study centers could proceed as planned, and we would like to thank everyone involved. We are confident that the study results will bring us a step closer to preventing GvHD via the specific activation of regulatory T cells,” added Dr. Helmut Jonuleit, CSO and Head of Production for ActiTrexx.
 

About GvHD
GvHD is a life-threatening side effect of allogeneic haematopoietic stem cell transplantation. Donor lymphocytes react against tissue antigens in the recipient and cause severe organ and tissue damage, that often takes a chronic course. GvHD is primarily triggered by the donor’s CD4⁺ T cells, whose activity is controlled by regulatory T cells. About 50% of patients develop the disease with a significantly increased mortality rate within 3 years after transplantation. Once developed, patients suffer from the often life-long symptoms.
 

About Actileucel
Actileucel is a cellular therapeutic agent that contains optimally activated regulatory T cells, the natural guardian cells of our immune system. Regulatory T cells modulate the activity of T cells and prevent unwanted inflammatory reactions. Actileucel suppresses the undesired activation of CD4⁺ T cells in the transplant, prevents the development of GvHD and promotes the development of a healthy immune system in the patient. The cellular therapeutic Actileucel is classified as an Advanced Therapy Medicinal Product (ATMP), produced in an automated process and ready for clinical use in patients within 24 hours.
 

About ActiTrexx
ActiTrexx is a clinical phase biotech company developing a platform of cellular and biologic therapies for overshooting T cell mediated autoimmune and autoinflammatory diseases with high medical unmet need. The first product candidate, Actileucel, is a cell therapy based on regulatory T cells that are activated in a proprietary ultrafast process, and is in clinical Phase Ib/II for the treatment of Graft-versus-Host Disease (GvHD) after blood stem cell transplantation. ActiTrexx GmbH was founded in 2020 as a spin-off from the University Medical Center Mainz and is backed by LBBW Venture Capital GmbH, High-Tech Gründerfonds (HTGF), Investitions- und Strukturbank Rheinland-Pfalz (ISB) and MediVentures GmbH. www.actitrexx.de
 

Ad hoc Announcement

in acc. with Article 17 (1) of the Market Abuse Regulation (MAR)

MAQUET Medical Systems AG increases the amount of the cash compensation for the transfer of the shares in Pulsion Medical Systems SE to be EUR 20,67

Feldkirchen, 17 October 2025

MAQUET Medical Systems AG, registered office: Rastatt, Kehler Straße 31, 76437 Rastatt (AG Mannheim HRB 719044), has increased the cash compensation set at EUR 20,57 per share on 17 October 2025 as part of the transfer request addressed to Pulsion Medical Systems SE, registered office: Feldkirchen, Hans-Riedl-Str. 21, 85622 Feldkirchen (AG Munich HRB 192563) pursuant to Art. 9 (1) (c) (ii) of the Regulation on the Statute for a European Company (SE) in conjunction with Section 327a (1) of the German Stock Corporation Act (AktG) to EUR 20,67 due to changes of capital market data. MAQUET Medical Systems AG stated that it would propose a corresponding resolution at the extraordinary general meeting of Pulsion Medical Systems SE on 17 October 2025 accordingly.

The court-appointed expert auditor, who confirmed the appropriateness of the originally determined cash compensation on 28 August 2025 has already indicated that, based on the current status, he will confirm the appropriateness of the increased cash compensation.

Pulsion Medical Systems SE

Hans-Riedl-Str. 21

85622 Feldkirchen

investor@pulsion.com

Phone: +49 89 459 914 0

Contact:

Contact person:

Investor Relations

PULSION Medical Systems SE

Stephan Haft

Managing Director

Phone: +49 89 / 459914 0

Fax: +49 89 / 459914 368

E-mail: info@pulsion.com

End of Inside Information

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014

M1 Kliniken AG: HAEMATO AG sells its 100% subsidiary HAEMATO Pharm GmbH to PHOENIX group

M1 Kliniken AG announces that its 85% subsidiary, HAEMATO AG, today signed an agreement for the sale of its wholly owned subsidiary HAEMATO Pharm GmbH to the PHOENIX group, one of Europe’s leading healthcare providers headquartered in Mannheim. The completion of the transaction remains subject to the customary antitrust approvals. The parties have agreed not to disclose the financial details of the transaction.

With this transaction, M1 Kliniken AG is consistently pursuing its strategic course to position itself as a globally leading, vertically integrated pure-play provider in the field of medical aesthetics.

Contact:
Attila Strauss, Management Board
Corporate Communications
E-Mail: ir@m1-kliniken.de

Press Release // October 16, 2025
 

Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea^® biosimilar FYB203 (aflibercept) for Australia and Latin America
 

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) announces that Klinge Biopharma GmbH (“Klinge”), the exclusive owner of the global commercialization rights of Formycon’s Eylea^®1 biosimilar FYB203 (aflibercept), concluded an exclusive license agreement with Actor Pharmaceuticals Pty. Ltd. (“Actor”) for the commercialization of FYB203 in Australia. Furthermore, for Latin America, Klinge has signed an exclusive license agreement with Megalabs S.A. (“Megalabs”).

Upon signature of the agreements, Klinge is eligible to receive upfront and milestone payments, plus royalties on net sales. Formycon will participate in the mid-single-digit to low-double-digit percentage range in all payment streams to Klinge resulting from these agreements. Furthermore, Formycon will act as authorized designee to organize the supply chain for FYB203 and will receive additional service payments and a volume-based profit component for organizing the commercial market supplyon behalf of Klinge.

“Severe retinopathies are on the rise worldwide due to demographic trends and the increasing number of diabetes cases, which can lead to retinal diseases. With the partnerships for Australia and Latin America, Klinge has laid the foundation for making our Eylea^® biosimilar FYB203 available as an effective and cost-efficient treatment option in further important regions of the world. With Actor and Megalabs, we have gained two strong distribution partners with excellent regional networks and a profound local market knowledge. Together, we are focused on improving the treatment options for the many patients who have been underserved in the past. At the same time, we are contributing to reduce the financial burden on healthcare systems,” says Nicola Mikulcik, Chief Business Officer (CBO) of Formycon AG.

Actor Pharmaceuticals is an established Australian pharmaceutical company specializing in the registration and commercialisation of innovative medicines and biosimilars in Australia. With a strong commitment to quality, patient access, and long-term partnerships, Actor Pharmaceuticals collaborates with global industry leaders to bring clinically proven therapies to the Australian market. The company’s expertise spans product registration, market access, and commercialization – driving growth across both prescription and over-the-counter segments.

Megalabs is a leading pharmaceutical company based in Uruguay with a strong presence and market position in the Americas. Megalabs is at the cutting edge of biotechnological innovation, with its High-Tech business unit serving as one of the main pillars of the organization’s success. The company’s various business areas also include the development, manufacturing and marketing of biosimilar products.

In June 2024, the aflibercept biosimilar FYB203 was approved by the US Food and Drug Administration (“FDA”). Approval by the European Commission followed in January 2025 and approval by the British MHRA one month later. For Australia, the regulatory application has been submitted to the Therapeutic Goods Administration (“TGA”). Formycon is also working closely with Megalabs to prepare the applications for approval in Latin American countries.²

Eylea^® (aflibercept) is used to treat neovascular age-related macular degeneration (nAMD) and other severe retinal diseases. The active ingredient inhibits the vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of blood vessels in the retina.

———————–

¹⁾  Eylea^® is a registered trademark of Regeneron Pharmaceuticals Inc.

²⁾  The commercial launch of FYB203 in Australia and Latin America depends on several factors – firstly on approval by the respective regional regulatory authorities, and secondly on the progress and outcome of ongoing or potential future patent litigation or possible settlement agreements.

About Formycon:
Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/ranibizumab and FYB202/ustekinumab, Formycon already has two biosimilars on the market. Another biosimilar, FYB203/aflibercept, has been approved by the FDA, EMA, and MHRA. Four pipeline candidates are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines.

Formycon AG is headquartered in Munich, listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY and is part of the SDAX selection index. Further information can be found at: https://www.formycon.com/

About Biosimilars:
Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare systems. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.

About Actor Pharmaceuticals:
Actor Pharmaceuticals is a privately held pharmaceutical company dedicated to improving access to high-quality, clinically proven healthcare products across Australia and New Zealand. With a focus on trusted European brands, innovation, and patient well-being, Actor partners with global manufacturers to introduce and grow consumer and prescription health solutions in the region. Backed by deep industry expertise and a long-term vision, Actor Pharmaceuticals is committed to building enduring brands that make a meaningful difference in people’s lives.

About Megalabs:
Megalabs is a pharmaceutical company committed to providing healthcare professionals and consumers with affordable therapeutic solutions for a healthier and more fulfilling life. The company is present in 20 countries, with more than 8,000 collaborators, and offers more than 1,800 products that span all therapeutic areas. Its continuous growth is supported by 18 production plants, a highly diversified portfolio with more than 1,800 products, and 12 R&D centers. Megalabs is a forward-looking company with an established reputation as one of the leading pharmaceutical players in the Americas.

Contact:
Sabrina Müller
Director Investor Relations and Corporate Communications
Formycon AG
Fraunhoferstr. 15
82152 Martinsried/Planegg
Germany

phone +49 (0) 89 – 86 46 67 149
fax + 49 (0) 89 – 86 46 67 110
Sabrina.Mueller@formycon.com

Disclaimer:
This press release may contain forward-looking statements and information which are based on Formycon’s current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.